Cargando…
Nail Society of India (NSI) Recommendations for Pharmacologic Therapy of Onychomycosis
Onychomycosis (OM) is the commonest cause of dystrophic nails, responsible for upto 50% of cases. Apart from significantly damaging the nails, quality of life, and self-image of the sufferer, it also acts as a reservoir of fungal infections carrying important implications for emerging recalcitrant d...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231711/ https://www.ncbi.nlm.nih.gov/pubmed/37266092 http://dx.doi.org/10.4103/idoj.idoj_355_22 |
_version_ | 1785051791120924672 |
---|---|
author | Mahajan, Khushbu Grover, Chander Relhan, Vineet Tahiliani, Sushil Singal, Archana Shenoy, M Manjunath Jakhar, Deepak |
author_facet | Mahajan, Khushbu Grover, Chander Relhan, Vineet Tahiliani, Sushil Singal, Archana Shenoy, M Manjunath Jakhar, Deepak |
author_sort | Mahajan, Khushbu |
collection | PubMed |
description | Onychomycosis (OM) is the commonest cause of dystrophic nails, responsible for upto 50% of cases. Apart from significantly damaging the nails, quality of life, and self-image of the sufferer, it also acts as a reservoir of fungal infections carrying important implications for emerging recalcitrant dermatophytoses. Treatment of OM is based on guidelines released almost a decade back, in addition to published literature and personal preferences. Hence, an expert group of nail society of India (NSI) worked towards drafting these guidelines aimed at compiling recommendations for pharmacologic treatment of OM, based on scientific evidence, along with practical experience. The group did an extensive analysis of available English language literature on OM published during the period 2014–2022. The evidence compiled was graded and discussed to derive consensus recommendations for practice. Special focus was placed on combination therapies and adjunct therapies, including experience of members, to improve treatment outcomes. |
format | Online Article Text |
id | pubmed-10231711 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-102317112023-06-01 Nail Society of India (NSI) Recommendations for Pharmacologic Therapy of Onychomycosis Mahajan, Khushbu Grover, Chander Relhan, Vineet Tahiliani, Sushil Singal, Archana Shenoy, M Manjunath Jakhar, Deepak Indian Dermatol Online J Review Article Onychomycosis (OM) is the commonest cause of dystrophic nails, responsible for upto 50% of cases. Apart from significantly damaging the nails, quality of life, and self-image of the sufferer, it also acts as a reservoir of fungal infections carrying important implications for emerging recalcitrant dermatophytoses. Treatment of OM is based on guidelines released almost a decade back, in addition to published literature and personal preferences. Hence, an expert group of nail society of India (NSI) worked towards drafting these guidelines aimed at compiling recommendations for pharmacologic treatment of OM, based on scientific evidence, along with practical experience. The group did an extensive analysis of available English language literature on OM published during the period 2014–2022. The evidence compiled was graded and discussed to derive consensus recommendations for practice. Special focus was placed on combination therapies and adjunct therapies, including experience of members, to improve treatment outcomes. Wolters Kluwer - Medknow 2023-04-27 /pmc/articles/PMC10231711/ /pubmed/37266092 http://dx.doi.org/10.4103/idoj.idoj_355_22 Text en Copyright: © 2023 Indian Dermatology Online Journal https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Review Article Mahajan, Khushbu Grover, Chander Relhan, Vineet Tahiliani, Sushil Singal, Archana Shenoy, M Manjunath Jakhar, Deepak Nail Society of India (NSI) Recommendations for Pharmacologic Therapy of Onychomycosis |
title | Nail Society of India (NSI) Recommendations for Pharmacologic Therapy of Onychomycosis |
title_full | Nail Society of India (NSI) Recommendations for Pharmacologic Therapy of Onychomycosis |
title_fullStr | Nail Society of India (NSI) Recommendations for Pharmacologic Therapy of Onychomycosis |
title_full_unstemmed | Nail Society of India (NSI) Recommendations for Pharmacologic Therapy of Onychomycosis |
title_short | Nail Society of India (NSI) Recommendations for Pharmacologic Therapy of Onychomycosis |
title_sort | nail society of india (nsi) recommendations for pharmacologic therapy of onychomycosis |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231711/ https://www.ncbi.nlm.nih.gov/pubmed/37266092 http://dx.doi.org/10.4103/idoj.idoj_355_22 |
work_keys_str_mv | AT mahajankhushbu nailsocietyofindiansirecommendationsforpharmacologictherapyofonychomycosis AT groverchander nailsocietyofindiansirecommendationsforpharmacologictherapyofonychomycosis AT relhanvineet nailsocietyofindiansirecommendationsforpharmacologictherapyofonychomycosis AT tahilianisushil nailsocietyofindiansirecommendationsforpharmacologictherapyofonychomycosis AT singalarchana nailsocietyofindiansirecommendationsforpharmacologictherapyofonychomycosis AT shenoymmanjunath nailsocietyofindiansirecommendationsforpharmacologictherapyofonychomycosis AT jakhardeepak nailsocietyofindiansirecommendationsforpharmacologictherapyofonychomycosis |